FR2808193B1 - Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers - Google Patents

Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers

Info

Publication number
FR2808193B1
FR2808193B1 FR0005295A FR0005295A FR2808193B1 FR 2808193 B1 FR2808193 B1 FR 2808193B1 FR 0005295 A FR0005295 A FR 0005295A FR 0005295 A FR0005295 A FR 0005295A FR 2808193 B1 FR2808193 B1 FR 2808193B1
Authority
FR
France
Prior art keywords
cancers
treatment
synthetic vectors
vectors
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0005295A
Other languages
English (en)
Other versions
FR2808193A1 (fr
Inventor
Mir Samir El
Frederic Trieble
Didier Betbeder
Anne Casanova
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovector Therapeutics SA
Original Assignee
Biovector Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0005295A priority Critical patent/FR2808193B1/fr
Application filed by Biovector Therapeutics SA filed Critical Biovector Therapeutics SA
Priority to JP2001577935A priority patent/JP2004508290A/ja
Priority to AU2001258476A priority patent/AU2001258476A1/en
Priority to EP01931773A priority patent/EP1276468A1/fr
Priority to PCT/FR2001/001289 priority patent/WO2001080836A1/fr
Priority to CA002406949A priority patent/CA2406949A1/fr
Publication of FR2808193A1 publication Critical patent/FR2808193A1/fr
Priority to US10/281,371 priority patent/US20040081686A1/en
Application granted granted Critical
Publication of FR2808193B1 publication Critical patent/FR2808193B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR0005295A 2000-04-26 2000-04-26 Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers Expired - Fee Related FR2808193B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR0005295A FR2808193B1 (fr) 2000-04-26 2000-04-26 Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers
AU2001258476A AU2001258476A1 (en) 2000-04-26 2001-04-26 Use of particulate vectors in immunomodulation
EP01931773A EP1276468A1 (fr) 2000-04-26 2001-04-26 Utilisation de vecteurs particulaires dans l' immunomodulation
PCT/FR2001/001289 WO2001080836A1 (fr) 2000-04-26 2001-04-26 Utilisation de vecteurs particulaires dans l'immunomodulation
JP2001577935A JP2004508290A (ja) 2000-04-26 2001-04-26 免疫調節における粒状ベクターの使用
CA002406949A CA2406949A1 (fr) 2000-04-26 2001-04-26 Utilisation de vecteurs particulaires dans l'immunomodulation
US10/281,371 US20040081686A1 (en) 2000-04-26 2002-10-25 Use of particle vectors in immunomodulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0005295A FR2808193B1 (fr) 2000-04-26 2000-04-26 Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers

Publications (2)

Publication Number Publication Date
FR2808193A1 FR2808193A1 (fr) 2001-11-02
FR2808193B1 true FR2808193B1 (fr) 2004-05-07

Family

ID=8849595

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0005295A Expired - Fee Related FR2808193B1 (fr) 2000-04-26 2000-04-26 Utilisation de l'il-2 et de vecteurs synthetiques dans le traitement des cancers

Country Status (1)

Country Link
FR (1) FR2808193B1 (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2624741B1 (fr) * 1987-12-21 1991-06-28 Pasteur Institut Compositions a base d'une combinaison de liposomes et de lymphokine presentant des proprietes immunostimulantes et leurs applications en medecine humaine et veterinaire
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals

Also Published As

Publication number Publication date
FR2808193A1 (fr) 2001-11-02

Similar Documents

Publication Publication Date Title
FR2746641B1 (fr) Utilisation d'un extrait d'au moins une iridacee dans le traitement des rides
FR2799369B1 (fr) Association d'escine et de sulfate de dextran et son utilisation
DE60041674D1 (de) Abrichtvorrichtung und Poliervorrichtung
IL205242A0 (en) Substituted oxazolidinones and their use in the field of blood coagulation
ID17156A (id) Zat-zat anti koagulan yang berguna dalam pengobatan trombosis
EE03512B1 (et) Epinastiin kasutamiseks valude ravis
EP1011610A4 (fr) Compositions pour soins de la peau et leur utilisation
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
DE69818554D1 (de) Körperhaarbehandlungsgerät
FR2812197B1 (fr) Utilisation de co dans le traitement de l'inflammation des voies aeriennes superieures ou des bronches
NO20006113D0 (no) Anvendelse av cyklosporiner i behandlingen av inflammatoriske autoimmune sykdommer
MA24332A1 (fr) Utilisation de 1-hydroxy-2- pyridones pour le traitement d'infections de la peau
GB2314273B (en) The use of TCET in the prophylaxis and treatment of allergies
IT1298470B1 (it) Composti impiegati nella prevenzione del cancro della mammella e uso degli stessi
EP0971949A4 (fr) Complexes et combinaisons de fetuine et d'agents therapeutiques
IT1320860B1 (it) Apparecchiatura per il trattamento di disgregazione di campionibiologici e dispositivo disgregatore per l'impiego in detta
EP1214040A4 (fr) Utilisation d'extraits de peau d'orange dans la prevention et le traitement du cancer
EP1567556A4 (fr) Immunotoxine recombinante et son utilisation dans le traitement de tumeurs
EP1100524A4 (fr) Utilisation d'uteroglobine humaine de recombinaison dans le traitement d'etats inflammatoires et de type fibreux
EP1198475A4 (fr) Facteur d'activation de la cytokine hautement purifie et procedes d'utilisation
EP1572887A4 (fr) Peptides de regeneration neurale et procedes d'utilisation de ces derniers dans le traitement des lesions cerebrales
BR9709636A (pt) Uso de buckminsterfulereno no tratamento de ferimento neurotóxico
DE69803245D1 (de) Bilderzeugungsgerät und Bestimmung des angeschlossenen Geräts
FR2777567B1 (fr) Composes fluoro-silicones sous forme d'huile et leur utilisation en cosmetique
GB9603657D0 (en) Improvements in the treatment of vaginal infections

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20061230